Cell Therapeutics prepares for Pixuvri launch; posts 2nd-qtr results

1 August 2012

US biotech firm Cell Therapeutics (Nasdaq: CTIC) yesterday reported second-quarter 2012 financial results and recent accomplishments, including plans for the launch of its Pixuvri (pixantrone) in Europe during the fourth quarter of this year.

Pixuvri recently gained European conditional approval as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). Pixuvri is the first approved treatment in the European Union in this patient setting (The Pharma Letter May 14).

Noting other recent company highlights, Cell Thera said it had closed the acquisition of pacritinib, a highly selective JAK2 inhibitor, scheduled to enter Phase III clinical trial for treatment of patients with myelofibrosis in the fourth quarter of 2012 (TPL April 20).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK